Sign In
Buy RAPT
$58.02
+0 (+0%)
At Close: Jun 01, 2026
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
05:00am, Monday, 29'th Sep 2025
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing a
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet
10:56am, Monday, 18'th Aug 2025
The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross
10:55am, Tuesday, 12'th Aug 2025
After reaching an important support level, Rapt Therapeutics (RAPT) could be a good stock pick from a technical perspective. RAPT recently experienced a "golden cross" event, which saw its 50-day simp
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
08:00am, Thursday, 07'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company foc
Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade
10:56am, Friday, 01'st Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 122.2% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable,
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why
01:01pm, Tuesday, 15'th Jul 2025
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for July 15th
11:01am, Tuesday, 15'th Jul 2025
FUTU, IVZ and RAPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2025.
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?
10:56am, Tuesday, 15'th Jul 2025
The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
New Strong Buy Stocks for July 15th
06:56am, Tuesday, 15'th Jul 2025
FUTU, PAAS, RAPT, HG and IVZ have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2025.
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
08:00am, Monday, 23'rd Jun 2025
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know
10:55am, Wednesday, 18'th Jun 2025
The consensus price target hints at a 282.7% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
09:00am, Friday, 13'th Jun 2025
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discov
RAPT Therapeutics to Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 04'th Jun 2025
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 16'th May 2025
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RAPT Therapeutics Reports First Quarter 2025 Financial Results
08:00am, Thursday, 08'th May 2025
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focu
